China has approved the world's first invasive brain-computer interface (BCI) chip, marking a new milestone in restorative medical technology. The device has already enabled a quadriplegic patient to perform basic motor tasks, such as holding a pen to write.
Context
According to MIT Technology Review, patient Dong Hui (39, from Henan, China) suffered severe spinal cord injuries in a car accident six years ago, leaving him paralyzed from the neck down. Last October, thanks to this experimental implant, Dong was able to attempt writing again, offering hope for motor recovery for others in similar conditions.
Key Developments
The approval of this invasive chip underscores China's efforts to accelerate the commercialization and clinical application of BCI technology. Unlike non-invasive devices, invasive chips require surgical placement directly into the cerebral cortex to capture neural signals with higher precision, albeit with greater medical risks. However, detailed long-term safety data and the full regulatory licensing process still require verification through large-scale clinical trials.
Why It Matters
For the tech and medical communities, this event demonstrates the fierce competition in the global BCI race alongside Western rivals like Neuralink. China's official approval of an invasive device shows that the country's regulatory framework is becoming more receptive to sensitive biotechnology trials, posing both opportunities and challenges regarding bioethics and safety.